Decoding Nonadherence to Hypertensive Medication in New York City: A Population Segmentation Approach

Yan Li¹,², Foram Jasani¹, Dejun Su³, Donglan Zhang⁴, Lizheng Shi⁵, Stella S. Yi⁶, and José A. Pagán¹,⁷,⁸

Abstract

Objective: Nearly one-third of adults in New York City (NYC) have high blood pressure and many social, economic, and behavioral factors may influence nonadherence to antihypertensive medication. The objective of this study is to identify profiles of adults who are not taking antihypertensive medications despite being advised to do so. Methods: We used a machine learning–based population segmentation approach to identify population profiles related to nonadherence to antihypertensive medication. We used data from the 2016 NYC Community Health Survey to identify and segment adults into subgroups according to their level of nonadherence to antihypertensive medications. Results: We found that more than 10% of adults in NYC were not taking antihypertensive medications despite being advised to do so by their health care providers. We identified age, neighborhood poverty, diabetes, household income, health insurance coverage, and race/ethnicity as important characteristics that can be used to predict nonadherence behaviors as well as used to segment adults with hypertension into 10 subgroups. Conclusions: Identifying segments of adults who do not adhere to hypertensive medications has practical implications as this knowledge can be used to develop targeted interventions to address this population health management challenge and reduce health disparities.

Keywords

community health, disease management, health promotion, managed care, medications, primary care, prevention

Introduction

Termed the “silent killer,” hypertension, or high blood pressure, remains one of the leading causes of premature death worldwide and has become an important public health concern in major cities around the world.¹ According to Take Care New York 2020, the agenda of the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) for helping every New Yorker achieve healthier lives, controlling hypertension has become one of the city’s top priorities.² Hypertension has been referred to as the largest modifiable risk factor for heart disease and stroke, but the prevalence of hypertension in NYC has risen by 11% over the past decade.³ According to 2016 data, 1.8 million adults in NYC reported having hypertension, nearly 1 in 3 of the city’s adult population.³,⁴

Hypertension is a large public health concern in NYC, especially with regard to how it affects different population groups and neighborhoods within the city.⁵,⁶ For adults aged 65 years and older in NYC, nearly two-thirds reported having this condition in comparison with 11% of adults aged between 18 and 44 years. Prevalence varies by race and ethnicity; according to the most recent estimates using measured blood pressures, hypertension affects 43.5% of Black adults, 33% of Latino adults, 27.5% of White adults, and

¹The New York Academy of Medicine, New York, NY, USA
²Icahn School of Medicine at Mount Sinai, New York, NY, USA
³University of Nebraska Medical Center, Omaha, NE, USA
⁴University of Georgia, Athens, GA, USA
⁵Tulane University, New Orleans, LA, USA
⁶New York University School of Medicine, New York, NY, USA
⁷New York University, New York, NY, USA
⁸University of Pennsylvania, Philadelphia, PA, USA

Corresponding Author:
Yan Li, Center for Health Innovation, The New York Academy of Medicine, 1216 5th Avenue, New York, NY 10029, USA.
Email: yli@nyam.org

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Clinical practice guidelines for managing hypertension typically include strategies such as maintaining a healthy weight, being physically active, having a heart-healthy diet, and taking prescribed antihypertensive medications. For many adults with hypertension, taking medication as directed is a very effective way of getting blood pressure under control. Treatment with antihypertensive drugs also can result in significant reductions in severe cardiovascular outcomes, evidenced by studies showing a 20% to 25% reduction in acute coronary syndrome, a 30% to 35% reduction in stroke, and a 50% reduction in heart failure. Despite these health benefits, many adults with hypertension do not take their antihypertensive medications. Poor adherence to antihypertensive medication is associated with a higher incidence of cardiovascular disease and end-stage renal disease as well as increased mortality for adults with high blood pressure.

Population segmentation approaches have several advantages compared with traditional regression models in that (a) it makes no assumptions about the relationship of the underlying data, (b) it is flexible in handling missing data, and (c) it summarizes complex relationships and interactions into actionable clusters. Population segmentation has been used to, for example, identify population subgroups who refuse to reduce sodium consumption regardless of their risk of having cardiovascular disease and tailoring intervention efforts for integrated care and support to improve patient outcomes.

We used Exhaustive Chi-squared Automatic Interaction Detection (CHAID)—a machine learning approach—to determine the best predictors of nonadherence to antihypertensive medications while segmenting the population into different subcategories.

Exhaustive CHAID operates by cycling through 2 steps recursively. The first step is to perform optimal merging of all the splitting variables by conducting statistical association tests (ie, chi-square) over all possible combinations and then it merges splits of variables that have a weak association with the response variable. After all splitting variables have an optimally merged structure, the second step is to determine which variable should be used to split the data into clusters by conducting Bonferroni-adjusted chi-square tests of all splitting variables on the response variable and identifying the variable with the smallest P value. After a split is produced in the data, it begins again at the first step and continues the cycle until all the stopping criteria are met.
selected at random and then tested replicability with the rest one-third of the sample. Both the training and test sample sets resulted in the same segmentation subgroups. All analyses were conducted using IBM SPSS 25 (IBM Corp, Armonk, NY, USA).

**Results**

Table 1 presents the results from the population segmentation analysis. According to data from the 2016 CHS, about 10.2% of adults in NYC were not taking antihypertensive medication despite being advised to do so by their health care providers. The segmentation approach automatically divided the sample population into 10 groups based on their likelihood of following medical advice on hypertension medication. Each group was characterized by 2 or 3 key predictors. The variables identified through our analysis included age, neighborhood poverty, diabetes, household income, health insurance coverage, and race/ethnicity.

Age was the most important predictor (ie, level 1 predictor) of nonadherence to antihypertensive medication use. About 36% of adults aged 18 to 44 years did not adhere to medical advice for taking antihypertensive medication, while the nonadherence rates were 11.9% and 4.7% for adults aged 45 to 64 years and those 65 years and older, respectively (results not shown in Table 1). People from different age groups had different predictors of their choice of taking antihypertensive medication. Specifically, the 2 most important predictors for young adults aged 18 to 44 years were diabetes and race/ethnicity. About 12.3% of young adults with diabetes did not follow medical advice on antihypertensive medication (Population Group 3, Table 1), while the nonadherence rate increased to 41.6% for young adults without diabetes (combining Population Groups 1 and 2 with weights).

Being a white, Hispanic, or Asian further increased the nonadherence rate to 48% (Population Group 1, Table 1). The predictors for midlife adults aged 45 to 64 years were diabetes, health insurance coverage, and neighborhood poverty. All the midlife adults who had diabetes and lived in a low-poverty neighborhood followed their providers’ advice in taking antihypertensive medication (Population Group 7, Table 1), while 36.8% of midlife adults who were uninsured and without diabetes did not take antihypertensive medication as advised (Population Group 4, Table 1).

Finally, the primary predictors for older adults aged 65 years and older were neighborhood poverty and household income. The least adherent group among older adults—which had a nonadherence rate of 6.8%—were those who lived in a medium- or high-poverty neighborhood and whose household income was below 200% of federal poverty line (Population Group 9, Table 1).

**Discussion**

In this study, we used a machine learning approach to identify key demographic, clinical, and neighborhood level factors that can be used to classify hypertensive patients in NYC into groups based on the likelihood of following professional advice on taking antihypertensive medication. We found that age was the most important predictor of adherence to antihypertensive medication. Within each age group, different predictors came into play in influencing people’s behaviors. Being diagnosed with diabetes was identified as an important predictor among young and midlife adults, while neighborhood poverty level played an important role in medication adherence among midlife and older adults. Although our analysis included a broader set of independent variables and used a new approach, our findings are in general consistent with the literature.8,9

| Population Group | Level 1 Predictor | Level 2 Predictor | Level 3 Predictor | Nonadherence Rate (%) |
|------------------|-----------------|-----------------|------------------|-----------------------|
| 1                | Age 18-44 y     | No diabetes     | White, Asian, Hispanic | 48.0                  |
| 2                | Age 18-44 y     | No diabetes     | Black             | 31.1                  |
| 3                | Age 18-44 y     | Diabetes        | N/A               | 12.3                  |
| 4                | Age 45-64 y     | No diabetes     | Uninsured         | 36.8                  |
| 5                | Age 45-64 y     | No diabetes     | Insured, Medicare, Medicaid | 13.3                  |
| 6                | Age 45-64 y     | Diabetes        | Medium or high neighborhood poverty | 7.4                  |
| 7                | Age 45-64 y     | Diabetes        | Low neighborhood poverty | 0.0                  |
| 8                | Age 65 y or older | Medium or high neighborhood poverty | Household income >200 FPL | 4.0                  |
| 9                | Age 65 y or older | Medium or high neighborhood poverty | Household income <200 FPL | 6.8                  |
| 10               | Age 65 y or older | Low neighborhood poverty | N/A | 2.5                  |
| Overall nonadherence rate (%) |                  |                  |                  | 10.2                  |

Abbreviations: FPL, federal poverty line; N/A, not available.
Given that antihypertensive medication is the most effective means to achieve optimal blood pressure control and reduce the risk of severe cardiovascular disease outcomes, this study provides critical information to health care providers and policymakers on the specific patient groups they should prioritize and focus on to increase the rate of hypertension control and reduce associated disparities. Compared with regression analysis, population segmentation analysis can provide more actionable results which are easier to interpret and that can enable effective population health interventions specific for each segment.

This study has several limitations. First, we do not have access to other variables that could be related to nonadherence, such as the cost of drugs, side effects of medication, and geographical proximity to a health care provider. Second, we could not identify the causal relationship between independent factors and nonadherence behaviors due to the nature of our machine learning approach. However, the identification of important predictors could inform future research on causal inference. Finally, taking antihypertensive medication is only the first step in achieving optimal blood pressure control. Future research is needed to understand other important factors that may hamper optimal blood pressure control.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL141427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References
1. World Health Organization. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. http://apps.who.int/iris/bitstream/handle/10665/79059/WHO_DCO_WHD_2013.2_eng.pdf;jsessionid=767F9170ED028A1DA764CADAFA744D6B?sequence=1. Accessed January 21, 2019.
2. New York City Department of Health and Mental Hygiene (NYC DOHMH). Take Care New York (TCNY) 2020: Every Neighborhood, Every New Yorker Everyone’s Health Counts. New York: NYC DOHMH; 2017. https://www1.nyc.gov/assets/doh/downloads/pdf/tny/tny-2020.pdf. Accessed January 21, 2019.
3. New York City Department of Health and Mental Hygiene. Epiquery: NYC Interactive Health Data System—Community Health Survey 2016. https://a816-healthpsni.nyc.gov/epiquery/CHS/CHSXIndex.html. Accessed January 22, 2019.
4. Fei K, Rodriguez-Lopez JS, Ramos M, et al. Racial and ethnic subgroup disparities in hypertension prevalence, New York City Health and Nutrition Examination Survey, 2013-2014. Prev Chronic Dis. 2017;14:E33.
5. Angell SY, Garg RK, Gwynn RC, Bash L, Thorpe LE, Frieden TR. Prevalence, awareness, treatment, and predictors of control of hypertension in New York City. Circ Cardiovasc Qual Outcomes. 2008;1:46-53.
6. Borrell LN, Menendez BS, Joseph SP. Racial/ethnic disparities on self-reported hypertension in New York City: examining disparities among Hispanic subgroups. Ethn Dis. 2011;21:429-436.
7. Gosmanova EO, Kovesdy CP. Adherence to antihypertensive medications: is prescribing the right pill enough? Nephrol Dial Transplant. 2014;30:1649-1656.
8. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357-362.
9. Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 2012;27:57-64.
10. McCarty JA, Hastak M. Segmentation approaches in data-mining: a comparison of RFM, CHAID, and logistic regression. J Business Res. 2007;60:656-662.
11. Li Y, Berenson J, Moran AE, Pagán JA. Who does not reduce their sodium intake despite being advised to do so? A population segmentation analysis. Prev Med. 2017;99:77-79.
12. Vukic SI, Mayer EK, Darzi A. Patient segmentation analysis offers significant benefits for integrated care and support. Health Aff (Millwood). 2016;35:769-775.
13. McFarland W, Buzby G, Brown K, et al. Why do patients with hypertension discontinue medications? an analysis of claims data. J Gen Intern Med. 2012;27:138-145.

Author Biographies
Yan Li, PhD, is a Research Scientist at The New York Academy of Medicine and an Assistant Professor in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. His research interests include systems science modeling in population health and health care management, cost-effectiveness analysis, and big data analytics.

Foram Jasani, BDS, MPH, is a Senior Research Analyst in the Center for Evaluation and Applied Research at the New York Academy of Medicine. She received her MPH from Rutgers University and, before that, practiced Dental Surgery in Mumbai, India. She is interested in the statistical analysis of large datasets and health services research.

Dejun Su, PhD, received his PhD in sociology from the University of Chicago in 2006. He is currently an Associate Professor and Director of the Center for Reducing Health Disparities at the College of Public Health, University of Nebraska Medical Center. Dr. Su’s research focuses on social and cultural determinants of health, health care utilization, and health disparities.

Donglan Zhang, PhD, is an Assistant Professor at the Department of Health Policy and Management, College of Public Health,
University of Georgia. Dr. Zhang’s areas of expertise are in health services research, economic evaluation and policy impact analysis with application in chronic disease prevention and treatment.

Lizheng Shi, PhD, is a Regents Professor in Health Policy and Management and the Director for the Health Systems Analytics Research Center (HSARC) at the Tulane University School of Public Health and Tropical Medicine. Dr. Shi’s research focuses on health technology assessment and health policy to identify and address health disparities and promote health care quality, access, and cost.

Stella S. Yi, PhD, is a cardiovascular disease epidemiologist whose research focuses on community, clinical and policy-based initiatives for the reduction of chronic disease morbidity and mortality. She has a particular interest in improving cardio-metabolic health and lifestyle behaviors, including physical activity and nutrition in Asian American communities.

José A. Pagán, PhD, is Professor and Chair of the Department of Public Health Policy and Management in the College of Global Public Health at New York University and Director in Center for Health Innovation at The New York Academy of Medicine. He is also Adjunct Senior Fellow of the Leonard Davis Institute of Health Economics at the University of Pennsylvania and Chair of the National Advisory Committee of the Robert Wood Johnson Foundation’s Health Policy Research Scholars. His research interests include population health management, health care payment and delivery system reform, and the application of systems science in population health research.